Loading clinical trials...

Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet | Clinical Trials | Clareo Health

COMPLETED

Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet

NCT01376193•GlaxoSmithKline

Summary

The study is designed to investigate the information on safety and efficacy of naratriptan tablets on Japanese subjects with migraine headache during Japanese post-marketing surveillance period.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Subjects with migraine headache
•Must use naratriptan tablets for the first time

Exclusion Criteria

•Subjects with hypersensitivity to naratriptan
•Subjects with history, symptoms, or signs of myocardial infarction, ischemic cardiac disease, or variant angina
•Subjects with history of peripheral vascular disorder
•Subjects with history of cerebrovascular disorder or transient ischemic attacks
•Subjects with uncontrolled high-blood pressure
•Subjects with severe hepatic function disorder or renal function disorder
•Subjects taking ergotamine, ergotamine derivative containing product, or 5-HT1B/1D agonist

Key Dates

Start Date

April 1, 2009

Primary Completion Date

October 1, 2011

Completion Date

October 1, 2011

Last Updated

May 20, 2013

Enrollment

500

ACTUAL participants

Conditions

Migraine Disorders

Interventions

Naratriptan

DRUG

Mind Body Balance for Pediatric Migraine

NCT04715685

HeadacheHeadache Disorders+6 more

View study

RECRUITING

EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.

NCT05570149

Migraine Disorders

View study

RECRUITINGNA

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 20, 2013Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet

Inclusion Criteria

Exclusion Criteria

Mind Body Balance for Pediatric Migraine

EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.

Tai Chi for the Prophylaxis of Episodic Migraine: the Efficacy Examination and Mechanism Exploration

Valproate Versus Propranolol in Migraine

Botulinum Toxin Type A Blockade of the Sphenopalatine Ganglion in Treatment-refractory Chronic Migraine

Potential Osteocatabolic Effect Caused by Anti-CGRP mAbs in Migraine Patients Treated With Anti-CGRP mAbs - an Observational Pilot Project With Prospectively Collected Health Related Data